These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
548 related articles for article (PubMed ID: 27907908)
1. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer. Chao A; Chang TC; Lapke N; Jung SM; Chi P; Chen CH; Yang LY; Lin CT; Huang HJ; Chou HH; Liou JD; Chen SJ; Wang TH; Lai CH Oncotarget; 2016 Dec; 7(51):85529-85541. PubMed ID: 27907908 [TBL] [Abstract][Full Text] [Related]
2. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer. Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585 [TBL] [Abstract][Full Text] [Related]
3. BRCA1/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients. Lee A; Kang J; Lee H; Lee YS; Choi YJ; Lee KH; Nistala GJ; Scafe CR; Choi J; Yoo J; Han M D E; Kim Y; Kim M Pathol Res Pract; 2019 Nov; 215(11):152595. PubMed ID: 31570282 [TBL] [Abstract][Full Text] [Related]
4. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing. Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875 [TBL] [Abstract][Full Text] [Related]
5. Recurrent BRCA1 Mutation, but no BRCA2 Mutation, in Vietnamese Patients with Ovarian Carcinoma Detected with Next Generation Sequencing. Vu HA; Phu ND; Khuong LT; Hoa PH; Nhu BTH; Nhan VT; Thanh LQ; Sinh ND; Chi HT; Quan ND; Binh NT Asian Pac J Cancer Prev; 2020 Aug; 21(8):2331-2335. PubMed ID: 32856862 [TBL] [Abstract][Full Text] [Related]
6. Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples. Zakrzewski F; Gieldon L; Rump A; Seifert M; Grützmann K; Krüger A; Loos S; Zeugner S; Hackmann K; Porrmann J; Wagner J; Kast K; Wimberger P; Baretton G; Schröck E; Aust D; Klink B BMC Cancer; 2019 Apr; 19(1):396. PubMed ID: 31029168 [TBL] [Abstract][Full Text] [Related]
7. Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues. Kim ET; Jeong HE; Yoon HJ; Kim KH; Suh DS Taiwan J Obstet Gynecol; 2023 Jan; 62(1):66-70. PubMed ID: 36720553 [TBL] [Abstract][Full Text] [Related]
8. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population. Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829 [TBL] [Abstract][Full Text] [Related]
9. BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls. Li A; Xie R; Zhi Q; Deng Y; Wu Y; Li W; Yang L; Jiao Z; Luo J; Zi Y; Sun G; Zhang J; Shi Y; Liu J Gynecol Oncol; 2018 Oct; 151(1):145-152. PubMed ID: 30078507 [TBL] [Abstract][Full Text] [Related]
10. Detection of somatic BRCA1/2 mutations in ovarian cancer - next-generation sequencing analysis of 100 cases. Koczkowska M; Zuk M; Gorczynski A; Ratajska M; Lewandowska M; Biernat W; Limon J; Wasag B Cancer Med; 2016 Jul; 5(7):1640-6. PubMed ID: 27167707 [TBL] [Abstract][Full Text] [Related]
11. Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples. Badoer C; Garrec C; Goossens D; Ellison G; Mills J; Dzial M; El Housni H; Berwouts S; Concolino P; Guibert-Le Guevellou V; Delnatte C; Del Favero J; Capoluongo E; Bézieau S Oncotarget; 2016 Dec; 7(49):81357-81366. PubMed ID: 27793035 [TBL] [Abstract][Full Text] [Related]
12. Prevalence of germline pathogenic Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677 [TBL] [Abstract][Full Text] [Related]
13. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients. Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111 [TBL] [Abstract][Full Text] [Related]
14. BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer. Shi T; Wang P; Xie C; Yin S; Shi D; Wei C; Tang W; Jiang R; Cheng X; Wei Q; Wang Q; Zang R Int J Cancer; 2017 May; 140(9):2051-2059. PubMed ID: 28176296 [TBL] [Abstract][Full Text] [Related]
15. Somatic mutations in BRCA1&2 in 201 unselected ovarian carcinoma samples - single institution study. Kowalik A; Zalewski K; Kopczyński J; Siołek M; Lech M; Hińcza K; Kalisz J; Chrapek M; Zięba S; Furmańczyk J; Jedliński M; Chłopek M; Misiek M; Góźdź S Pol J Pathol; 2019; 70(2):115-126. PubMed ID: 31556562 [TBL] [Abstract][Full Text] [Related]
16. Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma. Gornjec A; Novakovic S; Stegel V; Hocevar M; Pohar Marinsek Z; Gazic B; Krajc M; Skof E BMC Cancer; 2019 Apr; 19(1):296. PubMed ID: 30940100 [TBL] [Abstract][Full Text] [Related]
17. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study. Cheng HF; Tsai YF; Liu CY; Hsu CY; Lien PJ; Lin YS; Chao TC; Lai JI; Feng CJ; Chen YJ; Chen BF; Chiu JH; Tseng LM; Huang CC Breast Cancer Res; 2023 Dec; 25(1):152. PubMed ID: 38098088 [TBL] [Abstract][Full Text] [Related]
18. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854 [TBL] [Abstract][Full Text] [Related]
19. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil. Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478 [TBL] [Abstract][Full Text] [Related]
20. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]